Parabilis Medicines Q2 2026 Financial Results and Updates
Biotechnology
Earnings
IPO:
Jun 10, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Business Updates
Aug 13, 2026 8:05 AM ET
CAMBRIDGE, Mass., USA - Parabilis Medicines (Nasdaq: PBLS) reported its financial results for the second quarter ended June 30, 2026, alongside key business updates, highlighted by progress with its lead candidate zolucatetide and a strategic collaboration with Regeneron.
... Read on — Members only
About Parabilis Medicines, Inc.
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
Biotechnology
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.